Understand what’s happening inside your body today. miCheckup is miRoncol’s blood-based test that analyzes molecular patterns linked to common solid tumours, offering a meaningful early look at your current cancer risk before conventional screening may detect changes.
This leaves a major gap: most cancers are found too late, when treatment options are fewer and outcomes are worse.
The miRoncol Real-time Multi-Cancer Early Risk Assessment helps fill that gap. By analyzing microRNA patterns associated with cancer biology, the test offers a molecular-level snapshot of your current cancer risk.
Our approach integrates biology and advanced data science:
Sensitive signals of early cancer-related cellular change
Identifies shared molecular patterns across cancers, trained on human data
Built on more than 11,000 samples with specificity above 99% and sensitivity above 90% for many common cancers
The result: meaningful insight into your current biological signals, designed to support earlier conversations with your physician.
The test is designed to identify molecular patterns linked to more than a dozen common solid tumours, including:
Together, these cancers represent the majority of cases that impact Canadians today.
The test is best suited for proactive, health-conscious individuals who:
This is an early risk assessment, not a diagnostic test. Results are designed to complement, not replace, physician-led evaluation and conventional screening programs.
The miRoncol Real-time Multi-Cancer Early Risk Assessment helps you see what’s happening inside your body today so you and your physician can decide if earlier follow-up is appropriate.